Pro-Apoptotic Activity of New Honokiol/Triphenylmethane Analogues in B-Cell Lymphoid Malignancies. 2016

Aleksandra Mędra, and Magdalena Witkowska, and Agata Majchrzak, and Barbara Cebula-Obrzut, and Michael Y Bonner, and Tadeusz Robak, and Jack L Arbiser, and Piotr Smolewski
Department of Experimental Hematology of Medical University of Lodz, Ciołkowskiego 2 Street, Lodz 93-510, Poland. olajeske@o2.pl.

Honokiol and triphenylmethanes are small molecules with anti-tumor properties. Recently, we synthesized new honokiol analogues (HAs) that possess common features of both groups. We assessed the anti-tumor effectiveness of HAs in B-cell leukemia/lymphoma cells, namely in chronic lymphocytic leukemia (CLL) cells ex vivo and in pre-B-cell acute lymphoblastic leukemia (Nalm-6), Burkitt lymphoma (BL; Raji), diffuse large B-cell lymphoma (DLBCL; Toledo) and multiple myeloma (MM; RPMI 8226) cell lines. Four of these compounds appeared to be significantly active against the majority of cells examined, with no significant impact on healthy lymphocytes. These active HAs induced caspase-dependent apoptosis, causing significant deregulation of several apoptosis-regulating proteins. Overall, these compounds downregulated Bcl-2 and XIAP and upregulated Bax, Bak and survivin proteins. In conclusion, some of the HAs are potent tumor-selective inducers of apoptosis in ex vivo CLL and in BL, DLBCL and MM cells in vitro. Further preclinical studies of these agents are recommended.

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D008223 Lymphoma A general term for various neoplastic diseases of the lymphoid tissue. Germinoblastoma,Lymphoma, Malignant,Reticulolymphosarcoma,Sarcoma, Germinoblastic,Germinoblastic Sarcoma,Germinoblastic Sarcomas,Germinoblastomas,Lymphomas,Lymphomas, Malignant,Malignant Lymphoma,Malignant Lymphomas,Reticulolymphosarcomas,Sarcomas, Germinoblastic
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001713 Biphenyl Compounds Whitish aromatic crystalline organic compounds made up of two conjoined BENZENE rings. Compounds, Biphenyl
D014320 Trityl Compounds Derivatives of triphenylmethane. Triphenylmethyl Compounds,Compounds, Triphenylmethyl,Compounds, Trityl
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic

Related Publications

Aleksandra Mędra, and Magdalena Witkowska, and Agata Majchrzak, and Barbara Cebula-Obrzut, and Michael Y Bonner, and Tadeusz Robak, and Jack L Arbiser, and Piotr Smolewski
April 2006, Seminars in hematology,
Aleksandra Mędra, and Magdalena Witkowska, and Agata Majchrzak, and Barbara Cebula-Obrzut, and Michael Y Bonner, and Tadeusz Robak, and Jack L Arbiser, and Piotr Smolewski
January 2014, Acta poloniae pharmaceutica,
Aleksandra Mędra, and Magdalena Witkowska, and Agata Majchrzak, and Barbara Cebula-Obrzut, and Michael Y Bonner, and Tadeusz Robak, and Jack L Arbiser, and Piotr Smolewski
November 2012, Expert opinion on drug metabolism & toxicology,
Aleksandra Mędra, and Magdalena Witkowska, and Agata Majchrzak, and Barbara Cebula-Obrzut, and Michael Y Bonner, and Tadeusz Robak, and Jack L Arbiser, and Piotr Smolewski
January 1991, Henry Ford Hospital medical journal,
Aleksandra Mędra, and Magdalena Witkowska, and Agata Majchrzak, and Barbara Cebula-Obrzut, and Michael Y Bonner, and Tadeusz Robak, and Jack L Arbiser, and Piotr Smolewski
February 1997, Cancer genetics and cytogenetics,
Aleksandra Mędra, and Magdalena Witkowska, and Agata Majchrzak, and Barbara Cebula-Obrzut, and Michael Y Bonner, and Tadeusz Robak, and Jack L Arbiser, and Piotr Smolewski
July 2010, Current drug targets,
Aleksandra Mędra, and Magdalena Witkowska, and Agata Majchrzak, and Barbara Cebula-Obrzut, and Michael Y Bonner, and Tadeusz Robak, and Jack L Arbiser, and Piotr Smolewski
September 2019, Immunological reviews,
Aleksandra Mędra, and Magdalena Witkowska, and Agata Majchrzak, and Barbara Cebula-Obrzut, and Michael Y Bonner, and Tadeusz Robak, and Jack L Arbiser, and Piotr Smolewski
September 2018, Journal of clinical medicine,
Aleksandra Mędra, and Magdalena Witkowska, and Agata Majchrzak, and Barbara Cebula-Obrzut, and Michael Y Bonner, and Tadeusz Robak, and Jack L Arbiser, and Piotr Smolewski
January 2016, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Aleksandra Mędra, and Magdalena Witkowska, and Agata Majchrzak, and Barbara Cebula-Obrzut, and Michael Y Bonner, and Tadeusz Robak, and Jack L Arbiser, and Piotr Smolewski
February 2011, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy,
Copied contents to your clipboard!